A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer
There are no current stratified medicine options for STK11-deficient NSCLC. STK11 loss mediates mTORC activation, GLUT1 up-regulation and increased…
Category: Targeted therapies
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
The discovery of the association between EGFR mutations and the efficacy of EGFR tyrosine-kinase inhibitors (TKIs) has revolutionized the tr…